Truist analyst Danielle Brill assumed coverage of Insmed (INSM) with a Buy rating and price target of $202, down from $214. The failure of the Brinsupri chronic rhinosinusitis without nasal polyps Phase 2 study is a “small wrinkle” in Insmed’s 2025 performance, the analyst tells investors in a research note. The firm views the corresponding valuation reset as a “great opportunity for investors” to buy the stock for the Brinsupri launch in non-cystic fibrosis bronchiectasis in 2026.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INSM:
- Insmed: Brinsupri-Led Growth, Pipeline Optionality, and Discounted Valuation Underpin Buy Rating
- Top 3 Trending Stocks, According to Analysts – 12/18/2025
- Insmed Stock (INSM) Sinks 18% as Analysts Cut Targets after Trial Failure
- Midday Fly By: Micron reports Q1 beat, Trump Media to merge with TAE
- Insmed falls -15.9%